More than half of today's unicorn health startups haven't published any influential research — and some experts say that raises the risk of another Theranos
1 min read
More than half of today’s unicorn health startups haven’t published any influential research — and some experts say that raises the risk of another Theranos
A new study suggests that many of the highest-valued healthcare startups — from buzzy health insurance companies like Oscar to biotechs with record-breaking IPOs like Moderna — are failing to publish quality scientific research. That could put us on the brink…